218 related articles for article (PubMed ID: 23928827)
1. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.
Touchon J; Lachaine J; Beauchemin C; Granghaud A; Rive B; Bineau S
Eur J Health Econ; 2014 Nov; 15(8):791-800. PubMed ID: 23928827
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.
Lachaine J; Beauchemin C; Legault M; Bineau S
Can J Psychiatry; 2011 Oct; 56(10):596-604. PubMed ID: 22014692
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
Pfeil AM; Kressig RW; Szucs TD
Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
Lopez OL; Becker JT; Wahed AS; Saxton J; Sweet RA; Wolk DA; Klunk W; Dekosky ST
J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):600-7. PubMed ID: 19204022
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
Jones RW; McCrone P; Guilhaume C
Drugs Aging; 2004; 21(9):607-20. PubMed ID: 15260515
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
8. [Cost of illness in Alzheimer's disease].
Kiencke P; Rychlik R; Grimm C; Daniel D
Med Klin (Munich); 2010 May; 105(5):327-33. PubMed ID: 20503006
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.
Hartz S; Getsios D; Tao S; Blume S; Maclaine G
BMC Neurol; 2012 Feb; 12():2. PubMed ID: 22316501
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
Getsios D; Blume S; Ishak KJ; Maclaine GD
Pharmacoeconomics; 2010; 28(5):411-27. PubMed ID: 20402542
[TBL] [Abstract][Full Text] [Related]
12. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
Deardorff WJ; Grossberg GT
Drug Des Devel Ther; 2016; 10():3267-3279. PubMed ID: 27757016
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Jönsson L
Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK.
Zala D; Chan D; McCrone P
Int J Geriatr Psychiatry; 2018 Feb; 33(2):307-315. PubMed ID: 28612928
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway.
Rive B; Aarsland D; Grishchenko M; Cochran J; Lamure M; Toumi M
Int J Geriatr Psychiatry; 2012 Jun; 27(6):573-82. PubMed ID: 21834130
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of galantamine in a german context].
Happich M; Schweikert B; Mühlbacher A
Psychiatr Prax; 2005 Apr; 32(3):142-50. PubMed ID: 15818530
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
Fuh JL; Wang SJ
Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
[TBL] [Abstract][Full Text] [Related]
18. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.
Hyde C; Peters J; Bond M; Rogers G; Hoyle M; Anderson R; Jeffreys M; Davis S; Thokala P; Moxham T
Age Ageing; 2013 Jan; 42(1):14-20. PubMed ID: 23179169
[TBL] [Abstract][Full Text] [Related]
19. Memantine for treatment of moderate to severe Alzheimer's disease.
Perras C
Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal medication usage in Alzheimer disease patients.
Zhu CW; Livote EE; Kahle-Wrobleski K; Scarmeas N; Albert M; Brandt J; Blacker D; Sano M; Stern Y
Alzheimer Dis Assoc Disord; 2010; 24(4):354-9. PubMed ID: 20625271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
